Skip to main content

Advertisement

Table 5 Incremental cost-effectiveness of 10- valent pneumococcal conjugate vaccine in terms of averted DALYs during three years follow-up from inclusion in the study in the intervention group, vaccinated sub-group (Sep. 2011 – Aug. 2012) and control group (Sep. 2009 – Aug. 2010) at Butajira rural health program site

From: Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation

Health outcomes Cost* Incremental cost Effectiveness Incremental effectiveness Incremental cost- effectiveness ratio (ICER)
  No discounting Discounting 3%
DALYs
 < 1 year of age
  Intervention 36.7 30.2 0.08 −0.01 Dominated Dominated
  Vaccinated 36.2 29.7 0.11 −0.04 Dominated Dominated
  Control 6.5   0.07    
 > 1 year of age
  Intervention 36.3 30.0 0.0001 0.14 219.4 227.9
  Vaccinated 32.9 26.6 0.0001 0.13 194.2 273.9
  Control 6.3   0.1338    
 > 2 years of age
  Intervention 31.0 29.2 0.00005 0.103 283.7 318.6
  Vaccinated 29.1 27.2 0.00003 0.1009 264.9 282.6
  Control 1.86   0.103    
 Total follow-up period
  Intervention 46.1 33.3 0.08 0.12 268.0 281.4
  Vaccinated 42.2 29.3 0.11 0.10 304.7 342.0
  Control 12.8   0.20    
  1. * N.B: the costs for averted DALYs and ALRI incidences are not the same due to the difference in considered costs. For DALYs, all costs in relation to all infections and vaccination were considered. In the case of ALRI, only costs related to ALRI and vaccination were considered